CANCER:

Melanoma

Related cancers:

‹

Ocular Melanoma (92)

Uveal Melanoma (88)

Cutaneous Melanoma (84)

Mucosal Melanoma (27)

Ocular Melanoma (92)

Uveal Melanoma (88)

Cutaneous Melanoma (84)

Mucosal Melanoma (27)

›

BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials J Immunother Cancer - 4 days (New B)	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials J Immunother Cancer - 4 days - (New B)
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	binimetinib + STA-4783 Sensitive: D – Preclinical Oncogene - 1 week (New D)	binimetinib + STA-4783 Sensitive: D – Preclinical Oncogene - 1 week - (New D)
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	binimetinib + STA-4783 Sensitive: D – Preclinical Oncogene - 1 week (New D)	binimetinib + STA-4783 Sensitive: D – Preclinical Oncogene - 1 week - (New D)
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	STA-4783 Sensitive: D – Preclinical Oncogene - 1 week (New D)	STA-4783 Sensitive: D – Preclinical Oncogene - 1 week - (New D)
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	STA-4783 Sensitive: D – Preclinical Oncogene - 1 week (New D)	STA-4783 Sensitive: D – Preclinical Oncogene - 1 week - (New D)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline Sci Rep - 2 weeks (New A2)	nivolumab + ipilimumab Sensitive: A2 - Guideline Sci Rep - 2 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	ipilimumab Sensitive: B - Late Trials Sci Rep - 2 weeks (New B)	ipilimumab Sensitive: B - Late Trials Sci Rep - 2 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	nivolumab Sensitive: B - Late Trials Sci Rep - 2 weeks (New B)	nivolumab Sensitive: B - Late Trials Sci Rep - 2 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	pembrolizumab Sensitive: B - Late Trials Sci Rep - 2 weeks (New B)	pembrolizumab Sensitive: B - Late Trials Sci Rep - 2 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	pembrolizumab + ipilimumab Sensitive: C3 – Early Trials Sci Rep - 2 weeks (New C3)	pembrolizumab + ipilimumab Sensitive: C3 – Early Trials Sci Rep - 2 weeks - (New C3)
BRAF mutation BRAF mutation	Melanoma Melanoma	BRAF mutation BRAF mutation	Melanoma Melanoma	PD1 inhibitor + STAT3 inhibitor Sensitive: D – Preclinical Mol Ther Oncolytics - 2 weeks (New D)	PD1 inhibitor + STAT3 inhibitor Sensitive: D – Preclinical Mol Ther Oncolytics - 2 weeks - (New D)
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval Curr Probl Cancer - 3 weeks (New A1)	trametinib + dabrafenib Sensitive: A1 - Approval Curr Probl Cancer - 3 weeks - (New C4)
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval J Clin Oncol - 3 weeks (New A1)	trametinib + dabrafenib Sensitive: A1 - Approval J Clin Oncol - 3 weeks - (New C3)
BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks (New C2)	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks - (New C3)
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks (New C2)	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks - (New C3)
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks (New C2)	pembrolizumab + trametinib + dabrafenib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 3 weeks - (New C3)
TP53 wild-type TP53 wild-type	Melanoma Melanoma	TP53 wild-type TP53 wild-type	Melanoma Melanoma	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials Invest New Drugs - 3 weeks (New C3)	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials Invest New Drugs - 3 weeks - (New C3)
NRAS mutation NRAS mutation	Melanoma Melanoma	NRAS mutation NRAS mutation	Melanoma Melanoma	temozolomide + rivoceranib Sensitive: C3 – Early Trials Melanoma Res - 3 weeks (New C3)	temozolomide + rivoceranib Sensitive: C3 – Early Trials Melanoma Res - 3 weeks - (New C3)
KIT mutation KIT mutation	Melanoma Melanoma	KIT mutation KIT mutation	Melanoma Melanoma	temozolomide + rivoceranib Sensitive: C3 – Early Trials Melanoma Res - 3 weeks (New C3)	temozolomide + rivoceranib Sensitive: C3 – Early Trials Melanoma Res - 3 weeks - (New C3)
BRAF mutation BRAF mutation	Melanoma Melanoma	BRAF mutation BRAF mutation	Melanoma Melanoma	temozolomide + rivoceranib Sensitive: C3 – Early Trials Melanoma Res - 3 weeks (New C3)	temozolomide + rivoceranib Sensitive: C3 – Early Trials Melanoma Res - 3 weeks - (New C3)
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval	vemurafenib + atezolizumab + cobimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	dabrafenib Sensitive: A1 - Approval	dabrafenib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval	trametinib + dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval	vemurafenib + cobimetinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval	vemurafenib + cobimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	vemurafenib Sensitive: A1 - Approval	vemurafenib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	trametinib Sensitive: A1 - Approval	trametinib Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	nivolumab Sensitive: A1 - Approval	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	ipilimumab Sensitive: A1 - Approval	ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	ipilimumab Sensitive: A1 - Approval	ipilimumab Sensitive: A1 - Approval
PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	PD-L1 underexpression PD-L1 underexpression	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	dabrafenib Sensitive: A1 - Approval	dabrafenib Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	trametinib Resistant: A1 - Approval	trametinib Resistant: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	trametinib Sensitive: A1 - Approval	trametinib Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	trametinib Sensitive: A1 - Approval	trametinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	vemurafenib Sensitive: A1 - Approval	vemurafenib Sensitive: A1 - Approval
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	ipilimumab Sensitive: A1 - Approval	ipilimumab Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Melanoma Melanoma	BRAF V600E BRAF V600E	Melanoma Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval	encorafenib + binimetinib Sensitive: A1 - Approval
BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval	vemurafenib + cobimetinib Sensitive: A1 - Approval
LDH elevation LDH elevation	Melanoma Melanoma	LDH elevation LDH elevation	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	aldesleukin Sensitive: A1 - Approval	aldesleukin Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval	nivolumab / relatlimab Sensitive: A1 - Approval
HLA-A02:01 HLA-A02:01	Uveal Melanoma Uveal Melanoma	HLA-A02:01 HLA-A02:01	Uveal Melanoma Uveal Melanoma	tebentafusp Sensitive: A1 - Approval	tebentafusp Sensitive: A1 - Approval
No biomarker No biomarker	Melanoma Melanoma	No biomarker No biomarker	Melanoma Melanoma	BNT111 Sensitive: A1 - Approval	BNT111 Sensitive: A1 - Approval
BRAF V600 wild-type BRAF V600 wild-type	Melanoma Melanoma	BRAF V600 wild-type BRAF V600 wild-type	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A1 - Approval	nivolumab + ipilimumab Sensitive: A1 - Approval
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	TC Sensitive: A2 - Guideline	TC Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	TC Sensitive: A2 - Guideline	TC Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline	ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	temozolomide Sensitive: A2 - Guideline	temozolomide Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	trametinib Resistant: A2 - Guideline	trametinib Resistant: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline	vemurafenib + atezolizumab + cobimetinib Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	temozolomide Sensitive: A2 - Guideline	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	dacarbazine Sensitive: A2 - Guideline	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: A2 - Guideline	trametinib Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline	pembrolizumab + ipilimumab Sensitive: A2 - Guideline
BRAF mutation BRAF mutation	Melanoma Melanoma	BRAF mutation BRAF mutation	Melanoma Melanoma	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline	dabrafenib + granisetron intravenous Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline	trametinib + dabrafenib Sensitive: A2 - Guideline
NRAS mutation NRAS mutation	Melanoma Melanoma	NRAS mutation NRAS mutation	Melanoma Melanoma	binimetinib Sensitive: A2 - Guideline	binimetinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Melanoma Melanoma	BRAF V600 BRAF V600	Melanoma Melanoma	BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline	BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Melanoma Melanoma	NTRK1 fusion NTRK1 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Melanoma Melanoma	NTRK3 fusion NTRK3 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Melanoma Melanoma	NTRK2 fusion NTRK2 fusion	Melanoma Melanoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	dabrafenib + SNR1611 Sensitive: A2 - Guideline	dabrafenib + SNR1611 Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline	trametinib + dabrafenib Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Melanoma Melanoma	ROS1 fusion ROS1 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
KIT exon 11 mutation KIT exon 11 mutation	Melanoma Melanoma	KIT exon 11 mutation KIT exon 11 mutation	Melanoma Melanoma	sunitinib Sensitive: A2 - Guideline	sunitinib Sensitive: A2 - Guideline
KIT exon 11 mutation KIT exon 11 mutation	Melanoma Melanoma	KIT exon 11 mutation KIT exon 11 mutation	Melanoma Melanoma	nilotinib Sensitive: A2 - Guideline	nilotinib Sensitive: A2 - Guideline
KIT exon 13 mutation KIT exon 13 mutation	Melanoma Melanoma	KIT exon 13 mutation KIT exon 13 mutation	Melanoma Melanoma	sunitinib Sensitive: A2 - Guideline	sunitinib Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Melanoma Melanoma	BRAF V600K BRAF V600K	Melanoma Melanoma	dabrafenib Sensitive: A2 - Guideline	dabrafenib Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Melanoma Melanoma	ROS1 fusion ROS1 fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Melanoma Melanoma	NTRK3 fusion NTRK3 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Melanoma Melanoma	NTRK1 fusion NTRK1 fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
KIT exon 13 mutation KIT exon 13 mutation	Melanoma Melanoma	KIT exon 13 mutation KIT exon 13 mutation	Melanoma Melanoma	nilotinib Sensitive: A2 - Guideline	nilotinib Sensitive: A2 - Guideline
BRAF fusion BRAF fusion	Melanoma Melanoma	BRAF fusion BRAF fusion	Melanoma Melanoma	sorafenib Sensitive: A2 - Guideline	sorafenib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	ALK fusion ALK fusion	Melanoma Melanoma	crizotinib Sensitive: A2 - Guideline	crizotinib Sensitive: A2 - Guideline
ALK fusion ALK fusion	Melanoma Melanoma	ALK fusion ALK fusion	Melanoma Melanoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab + dabrafenib Sensitive: A2 - Guideline	pembrolizumab + dabrafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	talimogene laherparepvec Sensitive: A2 - Guideline	talimogene laherparepvec Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	CaT Sensitive: A2 - Guideline	CaT Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	CVD Sensitive: A2 - Guideline	CVD Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600K BRAF V600K	Cutaneous Melanoma Cutaneous Melanoma	encorafenib + binimetinib Sensitive: A2 - Guideline	encorafenib + binimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	dabrafenib Sensitive: A2 - Guideline	dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600E BRAF V600E	Cutaneous Melanoma Cutaneous Melanoma	vemurafenib Sensitive: A2 - Guideline	vemurafenib Sensitive: A2 - Guideline
BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	BRAF V600 BRAF V600	Cutaneous Melanoma Cutaneous Melanoma	pembrolizumab + trametinib Sensitive: A2 - Guideline	pembrolizumab + trametinib Sensitive: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline	PD1 inhibitor + talimogene laherparepvec Resistant: A2 - Guideline
No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	No biomarker No biomarker	Cutaneous Melanoma Cutaneous Melanoma	ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline	ipilimumab + talimogene laherparepvec Sensitive: A2 - Guideline

Melanoma

Associations(963)

Associations
(963)